Related Experiment Videos
erbB-2 antisense oligonucleotides inhibit the proliferation of breast carcinoma cells with erbB-2 oncogene
1Division of Medical Oncology, Vincent T. Lombardi Cancer Research Center, Georgetown University, Washington, DC 20007.
Abstract:
Amplification and overexpression of the erbB-2 oncogene is an unfavourable prognostic marker in human breast cancer and occurs in approximately 25% of breast carcinomas. We used erbB-2 antisense oligonucleotides to inhibit the proliferation of human breast cancer cell lines. erbB-2 antisense oligonucleotides (20 microM) inhibited the growth and DNA synthesis of breast cancer cell lines with an amplified erbB-2 gene by up to 60%. Control complementary sense oligonucleotides did not inhibit cellular proliferation at the same concentration but showed inhibitory effects at higher concentrations. There was no specific effect of erbB-2 antisense oligonucleotides on breast cancer cell lines that had no amplification of erbB-2. erbB-2 antisense oligonucleotides reduced erbB-2 protein levels, measured by immunohistochemistry, in a dose-dependent manner. erbB-2 sense oligonucleotides did not decrease the levels of erbB-2 protein. These data indicate that erbB-2 antisense oligonucleotides induce a specific inhibition of erbB-2 protein expression and that erbB-2 gene overexpression is important for the proliferation of the breast cancer cells that have been selected for erbB-2 amplification.
Insights
Antisense oligonucleotides targeting the erbB-2 oncogene specifically inhibited the proliferation of breast cancer cells with amplified erbB-2. This targeted approach reduced erbB-2 protein levels, demonstrating its importance in cancer cell growth.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Amplification and overexpression of the erbB-2 oncogene are unfavorable prognostic markers in human breast cancer, occurring in about 25% of cases.
- The erbB-2 oncogene plays a crucial role in the proliferation of certain breast cancer subtypes.
Purpose of the Study:
- To investigate the potential of erbB-2 antisense oligonucleotides to inhibit the proliferation of human breast cancer cell lines.
- To determine the specificity and efficacy of erbB-2 antisense oligonucleotides in targeting cancer cells with erbB-2 amplification.
Main Methods:
- Utilized erbB-2 antisense oligonucleotides to treat human breast cancer cell lines with varying erbB-2 gene amplification status.
- Measured cell growth, DNA synthesis, and erbB-2 protein levels (via immunohistochemistry) in response to antisense and sense oligonucleotides.
- Compared effects of antisense oligonucleotides on cell lines with and without erbB-2 amplification.
Main Results:
- erbB-2 antisense oligonucleotides inhibited growth and DNA synthesis by up to 60% in breast cancer cell lines with amplified erbB-2.
- No specific inhibitory effect was observed in cell lines lacking erbB-2 amplification.
- A dose-dependent reduction in erbB-2 protein levels was observed with antisense oligonucleotides, while sense oligonucleotides showed no such effect.
Conclusions:
- erbB-2 antisense oligonucleotides specifically inhibit erbB-2 protein expression.
- Overexpression of the erbB-2 gene is critical for the proliferation of breast cancer cells with erbB-2 amplification.
- Targeting erbB-2 with antisense oligonucleotides represents a potential therapeutic strategy for specific breast cancer subtypes.